Viewing Study NCT05231850


Ignite Creation Date: 2025-12-24 @ 4:45 PM
Ignite Modification Date: 2025-12-27 @ 8:51 AM
Study NCT ID: NCT05231850
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-02-09
First Post: 2022-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
Sponsor: The First Affiliated Hospital of Zhengzhou University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module